Pipeline

Debiopharm’s projects cover all molecule type proteins, peptides, small molecules

Oncology

Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
_ Debio 4126
Acromegaly – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 4127
Gastroenteropancreatic ​neuroendocrine tumor – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 4228
Oncology – Undisclosed
Undisclosed
_ Debio 0228
Oncology – CAIX-targeted radiotherapy
CAIX-targeted radiotherapy
_ Debio 4028
Oncology – IAP antagonist
IAP antagonist
Merck
Merck: Merck KGaA

Infectious disease

Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
_ Debio 1453
N. gonorrhoeae – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/S
A. baumannii – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/M
GI disorders – microbiome remodeling
microbiome remodeling
Takeda
_ FibroTrap™ (Debio 1561)
Infectious diseases – Sample prep. Technology
Sample prep. Technology
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X: CARB-X
Takeda: Takeda

Our commercialized products

  • Triptorelin

    Triptorelin is a gonadotropin releasing hormone (GnRH) agonist

    Discover
  • Oxaliplatin

    A major advance in the history of cancer treatment

    Discover

Clinical trials

Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.

More about clinical trials